Scarica l'app Stockscreener
4.385
4.79%
0.185
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
Savara Inc (SVRA) looking to reclaim success with recent performance - SETE News
Market Update: Savara Inc (SVRA) Sees Negative Movement, Closing at 4.20 - The Dwinnex
Savara Inc. Grants Inducement Awards to New Employee - MSN
A stock that deserves closer examination: Savara Inc (SVRA) - US Post News
Savara Inc’s Market Journey: Closing Strong at 4.40, Up 3.29 - The Dwinnex
Savara Inc. Grants Inducement Awards to New Employee - MyChesCo
Savara Inc (NASDAQ:SVRA) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Savara’s (SVRA) Market Outperform Rating Reaffirmed at JMP Securities - Defense World
Savara: Trial Successful, But I'm Only Half Convinced (NASDAQ:SVRA) - Seeking Alpha
Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities - MarketBeat
Boeing, crypto-exposed stocks, Savara surge premarket By Investing.com - Investing.com Canada
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congres - Business Wire
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (SVRA)’s stock chart: A technical perspective - US Post News
Savara Announces New Employment Inducement Grant - StockTitan
Savara Inc (SVRA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Savara (NASDAQ:SVRA) Stock Price Up 4.8% - MarketBeat
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
What is Savara Inc (SVRA) Stock Return on Shareholders’ Capital? - SETE News
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? - Insider Monkey
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? - Yahoo Finance
Savara Inc (NASDAQ:SVRA) Receives $11.17 Consensus Target Price from Analysts - MarketBeat
Savara Inc (NASDAQ:SVRA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Savara Inc. to Present at European Respiratory Society Congress 2024 - MSN
Savara Inc (SVRA) stock on the rise: An overview - US Post News
A History of Outperforming Analyst Forecasts and Beating the Odds: Savara Inc (SVRA) - SETE News
Savara Inc. Reports Strong Q2 2024 Results and Positive IMPALA-2 Trial Outcomes - MSN
Financial Metrics Exploration: Understanding Savara Inc (SVRA) Through Ratios - The Dwinnex
Savara Inc. to Present at European Respiratory Society Congress 2024 - MyChesCo
Savara Inc. Reports Strong Q2 2024 Results and Positive IMPALA-2 Trial Outcomes - MyChesCo
Is Savara Inc (SVRA) worth investing in despite its overvalued state? - US Post News
Is Savara Inc (SVRA) positioned for future growth? - SETE News
California State Teachers Retirement System Has $378,000 Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Price T Rowe Associates Inc. MD Has $168,000 Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 3.3% - Defense World
Savara Inc (NASDAQ:SVRA) Forecasted to Post FY2024 Earnings of ($0.48) Per Share - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 3.3% - MarketBeat
Savara Announces New Employment Inducement Grant - Lelezard
HC Wainwright Comments on Savara Inc's FY2024 Earnings (NASDAQ:SVRA) - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Reaffirmed by HC Wainwright - Defense World
why Savara Inc [SVRA] is a Good Choice for Investors After New Price Target of $10.79 - The DBT News
Savara to present at ERS Congress in Vienna By Investing.com - Investing.com Canada
Savara Inc (SVRA) can make a big difference with a little luck - SETE News
Savara to present at ERS Congress in Vienna - Investing.com
Savara to present at ERS Congress in Vienna By Investing.com - Investing.com UK
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 - Manchestertimes
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 - Business Wire
HC Wainwright Reaffirms "Buy" Rating for Savara (NASDAQ:SVRA) - MarketBeat
SVRA’s Stock Journey: What Investors Need to Know About Savara Inc’s Performance - The InvestChronicle
Savara (NASDAQ:SVRA) Announces Quarterly Earnings Results - MarketBeat
Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume - MarketBeat
Can you now get a good deal on Savara Inc’s shares? - US Post News
Savara stock maintains Outperform rating despite bottom line miss - Investing.com
Savara stock maintains Outperform rating despite bottom line miss By Investing.com - Investing.com Canada
Market Momentum Report: Savara Inc (SVRA)’s Positive Close at 4.10 - The Dwinnex
Savara stock maintains Outperform rating despite bottom line miss By Investing.com - Investing.com Australia
Savara (NASDAQ:SVRA) PT Lowered to $9.00 - MarketBeat
Savara (NASDAQ:SVRA) Price Target Cut to $9.00 - Defense World
Savara stock maintains Outperform rating despite bottom line miss By Investing.com - Investing.com UK
SVRA Stock Earnings: Savara Misses EPS for Q2 2024 - InvestorPlace
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update - Manchestertimes
1.26%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):